USE OF RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FOR THE TREATMENT OF TYPE 1 HYPERSENSITIVITY IN A LIVING ANIMAL INCLUDING HUMANS - diagram, schematic, and image 27
Back to USE OF RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FOR THE TREATMENT OF TYPE 1 HYPERSENSITIVITY IN A LIVING ANIMAL INCLUDING HUMANS , All Patents .